Browse by UCL people
Group by: Type | Date
Number of items: 24.
Article
Burchill, E;
Lymberopoulos, E;
Menozzi, E;
Budhdeo, S;
McIlroy, JR;
Macnaughtan, J;
Sharma, N;
(2021)
The Unique Impact of COVID-19 on Human Gut Microbiome Research.
Frontiers in Medicine
, 8
, Article 652464. 10.3389/fmed.2021.652464.
|
 |
|
Gegg, ME;
Menozzi, E;
Schapira, AHV;
(2022)
Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
Neurobiology of Disease
, 166
, Article 105663. 10.1016/j.nbd.2022.105663.
|
|
|
Jha, A;
Menozzi, E;
Oyekan, R;
Latorre, A;
Mulroy, E;
Schreglmann, SR;
Stamate, C;
... Bhatia, KP; + view all
(2020)
The CloudUPDRS smartphone software in Parkinson's study: cross-validation against blinded human raters.
npj Parkinson's Disease
, 6
(1)
, Article 36. 10.1038/s41531-020-00135-w.
|
|
|
Latorre, A;
Del Gamba, C;
Menozzi, E;
Balint, B;
Brugger, F;
Bhatia, KP;
(2019)
Abnormal DaTSCAN and Atypical Parkinsonism in SCA12.
Movement Disorders Clinical Practice
, 6
(5)
pp. 400-402.
10.1002/mdc3.12751.
|
|
Lee, C;
Menozzi, E;
Chau, K;
Schapira, AHV;
(2021)
Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Journal of Neurochemistry
, 159
(5)
pp. 826-839.
10.1111/jnc.15524.
|
|
Menozzi, E;
Mulroy, E;
Akbarian-Tefaghi, L;
Bhatia, KP;
Balint, B;
(2021)
Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations.
Parkinsonism & Related Disorders
, 88
pp. 116-128.
10.1016/j.parkreldis.2021.05.026.
|
|
Menozzi, E;
Schapira, AHV;
Blandini, F;
Avenali, M;
(2023)
Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.
Current Neurology and Neuroscience Reports
10.1007/s11910-023-01259-1.
(In press).
|
|
Menozzi, Elisa;
Mezabrovschi, Roxana;
Nazeer, Aleesa;
Anderson, Amelia;
Loefflad, Nadine;
Heslegrave, Amanda J;
Veleva, Elena;
... Schapira, Anthony HV; + view all
(2026)
Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease.
Journal of Parkinson’s Disease
10.1177/1877718X251413875.
(In press).
|
|
|
Menozzi, Elisa;
Schapira, Anthony HV;
(2025)
Prospects for Disease Slowing in Parkinson Disease.
Annual Review of Pharmacology and Toxicology
, 65
pp. 237-258.
10.1146/annurev-pharmtox-022124-033653.
|
|
|
Menozzi, Elisa;
Schapira, Anthony HV;
(2024)
The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
CNS Drugs
10.1007/s40263-024-01073-4.
(In press).
|
|
Menozzi, E;
Balint, B;
Latorre, A;
Valente, EM;
Rothwell, JC;
Bhatia, KP;
(2019)
Twenty years on: Myoclonus‐dystonia and ε‐sarcoglycan — neurodevelopment, channel, and signaling dysfunction.
Movement Disorders
10.1002/mds.27822.
(In press).
|
|
Menozzi, E;
Latorre, A;
Balint, B;
Bhatia, KP;
Dystonia in Handcuffs: A Picture Typical of Lesch-Nyhan Syndrome.
Movement Disorders Clinical Practice
10.1002/mdc3.12776.
(In press).
|
|
Menozzi, E;
Macnaughtan, J;
Schapira, AHV;
(2021)
The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance.
Annals of Medicine
, 53
(1)
pp. 611-625.
10.1080/07853890.2021.1890330.
|
|
|
Menozzi, E;
Macnaughtan, J;
Schapira, AHV;
(2020)
LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
Movement Disorders
10.1002/mds.28347.
(In press).
|
|
Menozzi, E;
Schapira, AH;
(2020)
Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
CNS Drugs
, 34
(9)
pp. 915-923.
10.1007/s40263-020-00746-0.
|
|
Menozzi, E;
Schapira, AHV;
(2021)
Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.
Frontiers in Neurology
, 12
, Article 694764. 10.3389/fneur.2021.694764.
|
|
|
Mulroy, E;
Balint, B;
Latorre, A;
Schreglmann, S;
Menozzi, E;
Bhatia, KP;
Syringomyelia-Associated Dystonia: Case Series, Literature Review, and Novel Insights.
Movement Disorders Clinical Practice
10.1002/mdc3.12772.
(In press).
|
|
Mulroy, E;
Balint, B;
Menozzi, E;
Latorre, A;
Bhatia, KP;
(2019)
Benign tremulous parkinsonism of the young-consider Parkin.
[Letter].
Parkinsonism & Related Disorders
, 65
pp. 270-271.
10.1016/j.parkreldis.2019.05.027.
|
|
Mulroy, E;
Latorre, A;
Menozzi, E;
Teh, PC;
Magrinelli, F;
Bhatia, KP;
(2020)
Huntington disease like 2 (HDL-2) with parkinsonism and abnormal DAT-SPECT - A novel observation.
Parkinsonism & Related Disorders
, 71
pp. 46-48.
10.1016/j.parkreldis.2020.01.008.
|
|
Mulroy, E;
Menozzi, E;
Lees, AJ;
Lynch, T;
Lang, AE;
Bhatia, KP;
(2020)
Telemedicine in movement disorders – Leçons du COVID‐19.
Movement Disorders
, 35
(11)
pp. 1893-1896.
10.1002/mds.28297.
|
|
Mulroy, E;
Menozzi, E;
Lees, AJ;
Lynch, T;
Lang, AE;
Bhatia, KP;
(2020)
Reply to: A New Day: The Role of Telemedicine in Reshaping Care for Persons with Movement Disorders.
Movement Disorders
10.1002/mds.28315.
(In press).
|
|
Salgado, P;
Latorre, A;
Del Gamba, C;
Menozi, E;
Balint, B;
Bhatia, KP;
(2018)
SPG7: The Great Imitator of MSA‐C Within the ILOCAs.
Movement Disorders Clinical Practice
10.1002/mdc3.12711.
(In press).
|
|
Toffoli, M;
Chohan, H;
Mullin, S;
Jesuthasan, A;
Yalkic, S;
Koletsi, S;
Menozzi, E;
... Schapira, AHV; + view all
(2023)
Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study.
Neurobiology of Disease
, 188
, Article 106343. 10.1016/j.nbd.2023.106343.
|
Thesis
|
Menozzi, Elisa;
(2024)
Evolution of Clinical, Biochemical and Microbiome
Biomarkers of Conversion to Parkinson Disease in Glucocerebrosidase Mutation Carriers: Insights into Aetiology, Pathogenesis and Future Therapies.
Doctoral thesis (Ph.D), UCL (University College London).
|
